# Zoetis Inc. (ZTS) stock news and updates

As of November 20, 2026. Source: https://www.clearthesis.ai/updates/ZTS

## Our view on the Zoetis Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/ZTS

## Latest updates on Zoetis Inc.

### Zoetis won US approval for a new three-in-one chicken vaccine

*November 19, 2026 · product · significance: notable · signal: positive*

The U.S. Department of Agriculture licensed Poulvac Procerta HVT-ND-ILT, a vaccine that targets three major poultry diseases in a single dose. This addition to the livestock portfolio helps poultry farmers manage flock health more efficiently by reducing the number of separate shots required. While pet medicines for dogs and cats drive the company's highest profit margins, the livestock business provides a steady foundation. Expanding the poultry line with multi-disease vaccines helps protect this side of the business from competitors and supports overall revenue during periods when pet owners might be spending less.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261118551715/en/Zoetis-Receives-USDA-License-for-Poulvac%C2%AE-Procerta%C2%AE-HVT-ND-ILT-Vaccine-for-Chickens/)

### Zoetis won US approval for a longer-lasting dog allergy treatment

*November 11, 2026 · product · significance: notable · signal: positive*

Zoetis received a license from the USDA for Cytopoint Plus, a new version of its popular allergy treatment for dogs. This next-generation medicine is a monoclonal antibody, which is a type of protein designed to target specific causes of a disease. It provides 75 days of relief from itching in a single shot, roughly doubling the time between vet visits compared to the original version. This is a meaningful win because dermatology is one of the company's most profitable segments. By offering a longer-lasting injection, Zoetis makes it more convenient for pet owners and harder for rivals to compete with simpler pills. These specialized biologics are difficult to replicate, helping the company protect its market share even as generic competitors enter the animal health space.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261111108155/en/Zoetis-Receives-USDA-License-for-Cytopoint-Plus%E2%84%A2-The-First-and-Only-Long-Acting-Monoclonal-Antibody-Providing-75-Days-of-Allergic-Itch-Relief-in-Dogs-with-Allergic-Dermatitis/)

### We updated our thesis on Zoetis

*November 6, 2026 · news · significance: notable · signal: neutral*

After Zoetis reported its November results, we updated our fair value and cut our quality score to 3.6. We lowered our ratings for how the company is managed, its protection from competitors, and its sales growth. We have added the cost of writing down research assets and the impact of share buybacks on profit growth to what we track. We also reset our projections for the core U.S. pet business to account for customers switching to cheaper generic medicines.

### Zoetis earnings beat expectations despite a drop in pet care sales

*November 5, 2026 · earnings · significance: major · signal: neutral*

Zoetis reported earnings of $1.75 per share, which was higher than the $1.51 analysts expected. While total revenue of $2.4 billion also topped estimates, the underlying numbers show a divide in the business. Sales in the U.S. fell 6 percent as pet owners pulled back on vet visits and medicine, a trend the company has been facing for several months. Growth in livestock products and international markets helped balance out the weakness in U.S. pet care. Management felt confident enough in these other areas to raise their profit forecast for the full year. For long-term owners, the main question is whether the pet business is seeing a temporary dip or a more lasting shift in how people spend on their animals.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1555280/000155528026000048/0001555280-26-000048-index.htm)

### Morgan Stanley nudged its price target to $82

*November 4, 2026 · analyst · significance: minor · signal: neutral*

Morgan Stanley kept its overweight rating on the stock, which is a sign they expect it to perform better than the broader market. They lowered their target for the stock price from $85 to $82. This is a small adjustment that leaves their target slightly below where the stock is trading today. Across all Wall Street firms that follow the company, the average price target now sits at $85. These routine target tweaks are common as analysts adjust their models before the company reports its latest financial results.

Sources: [Morgan Stanley](https://thefly.com/ajax/news_get.php?id=4452843)

## Zoetis Inc. earnings

In Q3 2026, reported on November 5, 2026, Zoetis Inc. posted earnings of $1.75 per share against $1.51 expected, and revenue of $2.4 billion against $2.3 billion expected.

The next earnings report is expected on February 11, 2027. Analysts expect $1.22 per share. Revenue is expected around $2.2 billion.

What to watch: Whether Companion Animal Sales can return to growth, as this high-margin pet business is the primary engine for the company's long-term value.

## Recent analyst activity on ZTS

- October 29, 2026: Morgan Stanley Kept rating at Overweight, lowered target from $85. Price target: $82.00.
- October 27, 2026: UBS Kept rating at Neutral.

## What's ahead for Zoetis Inc.

- February 11, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/ZTS
